{"classes":[{"categories":[{"measurements":[{"comment":"The data is not evaluable as the samples were BLLQ.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"The data is not evaluable as the samples were BLLQ.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"The data is not evaluable as the samples were BLLQ.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"The data is not evaluable as the samples were BLLQ.","groupId":"OG003","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"19"}],"units":"Participants"}],"title":"Cycle 1 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"22.1","value":"341"},{"groupId":"OG003","spread":"105.5","value":"221"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"13"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 30 min Post Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.4","value":"283"},{"groupId":"OG001","spread":"40.8","value":"412"},{"groupId":"OG002","spread":"39.3","value":"301"},{"groupId":"OG003","spread":"58.0","value":"349"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"17"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.8","value":"293"},{"groupId":"OG001","spread":"28.9","value":"359"},{"groupId":"OG002","spread":"37.9","value":"291"},{"groupId":"OG003","spread":"36.4","value":"290"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"title":"Cycle 4 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"27.4","value":"701"},{"groupId":"OG003","spread":"29.5","value":"642"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"title":"Cycle 4 Day 1: 30 min Post Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.8","value":"67.7"},{"groupId":"OG001","spread":"17.0","value":"28.8"},{"groupId":"OG002","spread":"167.8","value":"38.5"},{"groupId":"OG003","spread":"119.9","value":"55.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"title":"Follow up on Month 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"56.6","value":"11.5"},{"groupId":"OG001","spread":"12.4","value":"5.38"},{"groupId":"OG002","spread":"412.2","value":"7.64"},{"groupId":"OG003","spread":"137.6","value":"15.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"title":"Follow up on Month 6, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"717.6","value":"0.237"},{"groupId":"OG001","spread":"119.3","value":"0.389"},{"groupId":"OG002","spread":"569.7","value":"0.162"},{"groupId":"OG003","spread":"18.7","value":"0.732"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"2"}],"units":"Participants"}],"title":"Follow up on Month 12, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1188.5","value":"0.00978"},{"groupId":"OG001","spread":"170.5","value":"0.0107"},{"groupId":"OG002","spread":"347.4","value":"0.00842"},{"groupId":"OG003","spread":"86.9","value":"0.0460"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}],"units":"Participants"}],"title":"Follow up on Month 18, Day 1"},{"categories":[{"measurements":[{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG000","spread":"NA","value":"0.00203"},{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG001","spread":"NA","value":"0.00203"},{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG003","spread":"NA","value":"0.00203"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"Follow up on Month 24, Day 1"},{"categories":[{"measurements":[{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG001","spread":"NA","value":"3.09"},{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG002","spread":"NA","value":"20.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Unscheduled"},{"categories":[{"measurements":[{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG003","spread":"NA","value":"0.0626"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"Unscheduled Visit: Pre-dose"},{"categories":[{"measurements":[{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG003","spread":"NA","value":"349"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"Unscheduled Visit: 30 min Post Dose"},{"categories":[{"measurements":[{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG000","spread":"NA","value":"367"},{"groupId":"OG002","spread":"52.7","value":"242"},{"groupId":"OG003","spread":"46.2","value":"232"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"title":"Study Treatment Completion Visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"19"}],"units":"Participants"}],"description":"Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG000","title":"Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL"},{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG001","title":"Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL"},{"description":"Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG002","title":"Arm E (Phase II Expansion): Pola+BG in FL"},{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG003","title":"Arm F (Phase II Expansion): Pola+BG in DLBCL"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK evaluable population included all the ITT participants who Cohort 1b (Phase 1b) and Arms E and F (Phase II) received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.","reportingStatus":"POSTED","timeFrame":"Cycles 1 and 4 Days 1: pre-dose and 30 min post dose; Cycle 2 Day1: pre-dose; Follow up visits on Day 1: Months 3, 6, 12, 18 and 24; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)","title":"Serum Concentration of Obinutuzumab","type":"SECONDARY","unitOfMeasure":"g/mL"}